Objective: The new seventh edition of the tumour, node and metastasis (TNM) classification now groups part of the #10 lymph nodes, which include the subcarinal space along with the inferior border of the main-stem bronchus (#10 below), as being a part of the 'subcarinal zone'. In this retrospective study, we aimed to evaluate the clinical significance of including the '#10 below' lymph node with the 'subcarinal zone'. Methods: Between 1980 and 2002, the locations of the 66 pN1 and 83 pN2 were found to be part of the bilateral lower lobe in 149 patients. The group comprised 107 males and 42 females, with ages ranging from 16 to 81 years (median: 61.4 years). The clinicopathological records were examined with regard to age, sex, nodal status, T factor and histological type. These variables were analysed as risk factors for superior mediastinal lymph node (SML) metastasis and prognosis. Results: Of 149 cases, 28 were #10 below positive/#7 negative (only #10 group), 29 were #10 below negative/#7 positive (only #7 group) and 37 were #10 below positive/#7 positive (double-positive group). There was a significantly higher incidence (64.9%, 24/37) of SML metastasis for the double-positive group as compared to only #10 (14.3%, 4/28) and only #7 groups (31.0%, 9/29) (P < 0.001). The overall 5-year survival rates for the only #10, only #7 and the double-positive groups were 50%, 28% and 22%, respectively (P = 0.02). Conclusions: As compared to #10 metastasis, #7 metastasis is a prognostic risk factor for highly advanced SML metastasis and a poorer prognosis. Therefore, since #10 below and #7 provide different types of diagnostic information, they may not be bundled together during patient evaluations. #
Introduction
Accurate staging of non-small-cell lung cancer (NSCLC) based on the tumour, node and metastasis (TNM) classification is used worldwide. The lung cancer-staging system was first developed in 1973. In 1986, Mountain proposed the current TNM classification [1] , with further revisions being made in 1997 [2] . Although this classification has been widely accepted, much debate still persists concerning the exact boundary between the N1 and N2 stations.
The seventh edition of the TNM classification is currently in the process of being revised and it is expected that the 'zone classification' will be adopted for classification of the pN factor [3, 4] . During the past few decades, two types of lymph node maps have been proposed, including Naruke's [5] and the American Thoracic Society (MD-ATS) maps [6] [7] [8] . Based on the seventh TNM classification, Japanese surgical cases were staged in accordance with the Naruke lymph node map [5] , which has been adopted as the official staging map by the Japan Lung Cancer Society [6] . All of the cases from other countries have been staged according to the MD-ATS map [7] [8] [9] . With regard to the seventh TNM classification reorganisation, Rusch et al. reported that 'The main discrepancy between these two lymph node maps is that the Naruke map considers lymph nodes in the subcarinal space along the inferior border of the main-stem bronchus (which we will refer to as '#10 below' in the remainder of the text) to be station 10 (hence, N1), whereas in the MD-ATS map, these are labeled as level 7 (and, therefore, N2)' [3, 4] .
In this retrospective study, we aimed to evaluate the clinical significance of including the '#10 below' lymph node with the 'subcarinal zone'.
Materials and methods
As this was a retrospective study and the individual patients were not identifiable, our Institutional Review Board waived the requirement to obtain patient consent.
A total of 1835 cases that underwent pulmonary resection for NSC primary lung cancers between January 1980 and December 2002 were found within the surgical files of the Cancer Institute Hospital, Tokyo, Japan. Of these cases, 1644 met the criteria of the Japanese Lung Cancer Society for curative pulmonary resection [10] . Curative resection was defined as a complete resection of the lung cancer with no evident cancer cells remaining. The absence of cancer cells was based on both surgical and pathological findings.
Staging definitions for T (primary tumour), N (regional lymph nodes) and M (distant metastasis) components were made according to the International Staging System for Lung Cancers [11] . Lymph node involvement was marked using the map of Naruke [5] . Lymph nodes were characterised as being invaded when direct extension or metastases were observed.
In this study, we define 'the nodes at the tracheal bifurcation' as being the #7 lymph node (N2), while 'the nodes around the main-stem bronchi' are defined as being the #10 lymph node (N1) [5, 12] . In addition, in #10 lymph node, the node presented at inferior border of the main-stem bronchus as being the #10 below lymph node (N1).
Histopathological studies were conducted according to the World Health Organization (WHO) criteria [13] . There were four surgeons involved in this study. All pulmonary resections and lymph node dissections were performed in the same way.
All patients underwent a preoperative assessment, which included chest X-ray, thoracic and upper abdomen computerised tomography (CT) scan, bone scan, brain magnetic resonance imaging (MRI) or CT, basic blood test and cardiopulmonary evaluation. Mediastinoscopy and positronemission tomography were not performed in this series.
To evaluate the clinical significance of including the #10 below lymph node in the 'subcarinal zone', we designated the location of the pN1 and pN2 tumours as both being part of the bilateral lower lobe. Therefore, we retrospectively analysed the pattern of lymph node metastasis in 149 out of the total 1644 patients. There were 107 men and 42 women, with a median age of 61.4 years (range: 16-81 years). The prognosis (survival rates) for cases with tumours of the bilateral lower lobe was 66% for patients with pN1 and 83% for patients with pN2. In patients that underwent complete resections, 77 (51.7%) had lobectomies, 46 (30.9%) had bilobectomies and 26 (17.4%) had pneumonectomies. Pathological examinations revealed that there were 32 (21.5%) T1 cases, 54 (36.2%) T2 cases, 12 (8.1%) T3 cases and 51 (34.2%) T4 cases. For the T4 cases, 50 patients had pulmonary metastasis. Using the WHO guidelines to classify the histological types in these patients, we determined that there were 98 adenocarcinomas, 38 squamous cell carcinomas, four large-cell carcinomas and 16 adenosquamous carcinomas. The clinical characteristics for these patients are summarised in Table 1 .
The duration of survival in this study was defined as the interval between the date of surgery and the date of death due to any cause over the 5-year postoperative period.
Survival rates from the date of operation were calculated using the Kaplan-Meier life-table method, with the differences in the observed survival rate between the groups tested using the log-rank test. Dichotomous variables are presented as percentages and were compared between groups using a chi-square or Fisher exact test when appropriate. A P-value < 0.05 was considered statistically significant. Statistical analysis was performed with the SPSS analytical software (SPSS Inc., Chicago, IL, USA).
Results

Distribution of lymph node involvement
Of the 149 study subjects, 65 cases (rt:lt = 34:31) had metastasis to the #10 below lymph node and 66 (rt:lt = 44:22) Totalhad metastasis to the #7 lymph node (Table 1 ). There were 37 cases (rt:lt = 24:13) with both #10 below and #7 metastasis (double-positive group), while 28 cases (rt:lt = 10:18) were positive for #10 below but negative for #7(only #10 group). There were 29 (rt:lt = 20:9) cases that were negative for #10 below but positive for #7 (only #7 group).
Superior mediastinal lymph node (SML; highest mediastinal nodes, paratracheal nodes, pretracheal nodes, anterior mediastinal nodes, posterior mediastinal nodes, tracheobronchial angle nodes, Botallo's nodes, para-aortic nodes and ascending aortic nodes) metastasis was seen in 43 (rt:lt = 28:15) cases, while 26 (rt:lt = 11:15) cases had #8.9 metastasis.
Patients with N1 disease were subdivided into two groups. Separation was based on the involvement of #10 below ('N1+', n = 20) or absence of involvement ('N1À', n = 46). Patients with N2 disease were also subdivided into two groups: those with involvement of only the #7 lymph node metastasis ('N2s', n = 25) and those with involvement of any other type of the pN2 lymph node ('N2o', n = 58). These groups were defined as the SML or the #8.9 positive groups. Table 2 summarises the associations between 'N1+' and 'N2s'. No significant association was found between the lymph node-metastasis distribution and age, gender, pT factor, tumour size, type of operation, pM factor and pathological type. However, a close association was demonstrated for location, as the N1+ had a significantly higher incidence (13 of 20, 65.0%) in the left lower lobe as compared to the right lower lobe. In contrast, the N2s had a lower incidence (7 of 25, 28.0%) in the left versus the right lobe (P = 0.01).
Associations between lymph node-metastasis distribution and clinicopathological variates
Associations among the double-positive, only #10 and only #7 groups are summarised in Table 3 . There was a significantly higher incidence (64.9%, 24/37) of SML metastasis for the double-positive group as compared to only #10 group (14.3%, 4/28) and only #7 group (31.0%, 9/29) (P < 0.001). 
Prognosis by type of lymph node involvement
The prognosis of patients with 'N1À', 'N1+', 'N2s' and 'N2o' were evaluated and the 5-year survival rates were 48%, 45%, 40% and 22%, respectively (Fig. 1) . Of the four groups, only 'N1À' and 'N2o' exhibited any significant difference (P < 0.01). The overall 5-year survival rates for the N2 with #7 only (n = 25) and for the other types (SML or #8.9 positive; n = 58) were 40% and 22%, respectively, although this difference was not statistically significant (P = 0.18) (Fig. 1) .
In the TNM sixth edition, the overall 5-year survival rates for the 66 pN1 and 83 pN2cases were 47% and 28%, respectively, and this difference was statistically significant (P < 0.001). After the re-organisation of the seventh TNM edition from the seventh edition, the N1+ cases (n = 20) were changed to pN2 from their previous pN1 classification, and thus, the overall 5-year survival rates for the 46 pN1 and 103 pN2cases were 48% and 31%, respectively. This difference was statistically significant (P = 0.001) (Fig. 2) .
The overall 5-year survival rates for the only #10 group, only #7 group and the double-positive group were 50%, 28% and 22%, respectively. Of the three groups, only #10 group versus only #7 group and only #10 group versus doublepositive group exhibited significant difference (P = 0.05 and 0.02, respectively) (Fig. 3) . Although the difference between only #7 group versus double-positive group was not statistically significant (P = 0.80) (Fig. 3) . The overall survival rates for the SML-negative (n = 106) and SML-positive (n = 43) cases were 43% and 19%, respectively. This difference was also significant (P = 0.004) (Fig. 4) .
Discussion
The major correction of the seventh TNM classification reorganisation involved the inclusion of the #10 below lymph node in the 'subcarinal zone'. In the current study, we only evaluated the prognoses of N1 with #10 below and N2 with #7, which were found to have 5-year survival rates of 45% and 40%, respectively (Fig. 1) . This difference was not statistically significant. The re-organisation of the sixth to the seventh TNM edition resulted in the N1 with #10 below cases being changed into pN2 from pN1. Therefore, the overall 5-year survival rates for the 46 pN1 and 103 pN2 cases that were classified according to the TNM seventh edition were 48% and 31%, respectively, and this difference was statistically significant (P = 0.001) (Fig. 2) . The changes that were implemented in the seventh TNM edition not only were correct but also quite understandable, as the N1+ cases are indeed a group that has a poor prognosis within pN1. Other reports have also shown that the prognoses for these groups to be identical. Asamura et al. [14] reported that N1 with #10 involvement and the single-station N2 survival curves could be superimposed. In addition, the 5-year survival rates were 54% and 53%, respectively. Rea et al. [15] also reported similar results, although the 5-year survival rates were 31% and 18%, respectively, which were not significant. Others authors [16] [17] [18] [19] have reported significantly worse survival rates for extra-lobar N1 disease as compared to intra-lobar N1 disease.
In the current study, the overall 5-year survival rates for SML-negative (n = 106) and SML-positive (n = 43) cases were 43% and 19%, respectively, a difference that was statistically significant (P = 0.004) (Fig. 4) . Okada et al. [20] observed that the patients with lower mediastinal metastasis had a significantly better prognosis than those with upper mediastinal metastasis, with 5-year survival rates of 24.8% and 0%, respectively, a difference that was statistically significant (P = 0.0446).
The most important finding of our current study concerned the prevalence of SML metastasis that occurred from the #10 positive and #7 negative and from the #7-positive cases. There was a significantly higher incidence (64.9%, 24/37) of SML metastasis for the double-positive group as compared to only #10 group (14.3%, 4/28) and only #7 group (31.0%, 9/29) (P < 0.001) ( Table 3) . From these results, the prognostic differences were calculated, with the overall 5-year survival rates for the only #10 group, only #7 group and the doublepositive group were 50%, 28% and 22%, respectively (P = 0.05) (Fig. 3) . The results suggest that the most important problem is the prevalence of SML metastasis and the integration of the #10 below and #7 lymph node within the 'subcarinal zone'.
An association was found between the #10 below and the #7 metastasis distribution. Our results demonstrated that there was a close relationship with the location that was involved. There was a significantly higher incidence of N1+ (13 of 20, 65.0%) in the left lower lobe as compared to the right lower lobe while the N2s had a lower incidence (7 of 25, 28.0%) in the left versus the right lobe (P = 0.01) ( Table 2) . This is the first time that this has been reported and the reason for this might be related to differences that exist for the anatomical length of the bilateral #10 below.
In conclusion, when examining survival rates for cases without SML metastasis, no problems are encountered when the #10 and #7 cases are bundled. However, as compared to #10 metastasis, #7 metastasis is a prognostic risk factor for highly advanced SML metastasis and poor patient outcome. Therefore, since #10 below and #7 provide different types of diagnostic information, they may not be bundled together during patient evaluations.
